Formica et al., 2020 - Google Patents
Clinical Utility of Plasma KRAS, NRAS and BRAF Mutational Analysis with Real Time PCR in Metastatic Colorectal Cancer Patients—The Importance of Tissue …Formica et al., 2020
View HTML- Document ID
- 11514107966598788335
- Author
- Formica V
- Lucchetti J
- Doldo E
- Riondino S
- Morelli C
- Argirò R
- Renzi N
- Nitti D
- Nardecchia A
- Dell’Aquila E
- Ferroni P
- Guadagni F
- Palmieri G
- Orlandi A
- Roselli M
- Publication year
- Publication venue
- Journal of Clinical Medicine
External Links
Snippet
Background: Tumor tissue (T) mutational analysis represents the standard for metastatic colorectal cancer (mCRC); however, circulating tumor DNA (ctDNA) detected by liquid biopsy in plasma (PL) can better represent tumor heterogeneity. Methods: mCRC patients …
- 210000001519 tissues 0 title abstract description 74
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/01—Social networking
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sant et al. | Role of ctDNA in breast cancer | |
Hysek et al. | Clinical routine TERT promoter mutational screening of follicular thyroid tumors of uncertain malignant potential (FT-UMPs): a useful predictor of metastatic disease | |
Pons-Belda et al. | Can circulating tumor DNA support a successful screening test for early cancer detection? The Grail paradigm | |
Shen et al. | KRAS G12D mutation subtype in pancreatic ductal adenocarcinoma: does it influence prognosis or stage of disease at presentation? | |
Park et al. | Circulating tumor DNA reflects uveal melanoma responses to protein kinase C inhibition | |
Carrasco et al. | Cell-free DNA as a prognostic biomarker for monitoring muscle-invasive bladder cancer | |
Masfarré et al. | ctDNA to guide adjuvant therapy in localized colorectal cancer (CRC) | |
Formica et al. | Clinical Utility of Plasma KRAS, NRAS and BRAF Mutational Analysis with Real Time PCR in Metastatic Colorectal Cancer Patients—The Importance of Tissue/Plasma Discordant Cases | |
Lee et al. | Clinical implication of liquid biopsy in colorectal cancer patients treated with metastasectomy | |
Lee et al. | Prognostic impact of perioperative CA19-9 levels in patients with resected perihilar cholangiocarcinoma | |
Galland et al. | Splenic volume as a surrogate marker of immune checkpoint inhibitor efficacy in metastatic non small cell lung cancer | |
Mazard et al. | Clinical relevance of viable circulating tumor cells in patients with metastatic colorectal cancer: the COLOSPOT prospective study | |
Verzè et al. | Monitoring cfDNA in plasma and in other liquid biopsies of advanced EGFR mutated NSCLC patients: a pilot study and a review of the literature | |
Zhu et al. | Evaluating the utility of ctDNA in detecting residual cancer and predicting recurrence in patients with serous ovarian cancer | |
Papadaki et al. | Assessment of the efficacy and clinical utility of different circulating tumor cell (CTC) detection assays in patients with chemotherapy-naive advanced or metastatic non-small cell lung cancer (NSCLC) | |
Tomioka-Inagawa et al. | The impact of neutrophil-to-lymphocyte ratio after two courses of pembrolizumab for oncological outcomes in patients with metastatic urothelial carcinoma | |
Sorroche et al. | PD-L1 tumor expression as a predictive biomarker of immune checkpoint inhibitors’ response and survival in advanced melanoma patients in Brazil | |
Reichert et al. | Multigene profiling of circulating tumor cells (CTCs) for prognostic assessment in treatment-naïve metastatic hormone-sensitive prostate cancer (mHSPC) | |
Morais et al. | Evaluation of ctDNA in the prediction of response to Neoadjuvant Therapy and Prognosis in locally advanced rectal Cancer patients: a prospective study | |
Shin et al. | The Clinical Implication of Conversion Surgery in Patients with Stage IV Gastric Cancer Who Received Systemic Chemotherapy | |
Loft et al. | Clinical applications of circulating tumour DNA in pancreatic adenocarcinoma | |
Braicu et al. | Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancer—Impact for Diagnosis and Treatment Monitoring | |
Ryu et al. | A preliminary study on the prognostic impact of neutrophil to lymphocyte ratio of the bronchoalveolar lavage fluid in patients with lung cancer | |
Levink et al. | Mutation analysis of pancreatic juice and plasma for the detection of pancreatic cancer | |
Sequeira et al. | OncoUroMiR: Circulating miRNAs for Detection and Discrimination of the Main Urological Cancers Using a ddPCR-Based Approach |